Specialist medical writing expertise in metabolic diseases
At Elion Medical Communications, we’re experienced in the field of metabolic diseases, particularly in relation to diabetes and obesity. Whether creating promotional content, crafting disease awareness campaigns or writing manuscripts, we have helped translate science for a variety of audiences, including healthcare professionals, patients, the general public and healthcare researchers.
Leading with experience
Our team at Elion includes experts in both medical writing and medical copywriting, enabling us to provide a broad range of services. Many of our writers have experience in metabolic diseases through projects at Elion and/or through their previous work in healthcare communications agencies, research, medicine, pharmacy, medical affairs within the pharmaceutical industry and medical device marketing.
Our writers have also worked across a number of regions worldwide, so we have experience with a range of healthcare systems and marketing regulations.
Our writing translates innovations in metabolic diseases
Numerous important developments in metabolic disease treatments have been seen in recent times, especially in obesity and type 2 diabetes.
At Elion, we’ve been proud to support a variety of clients, helping to translate complex science into engaging communications. With our deep understanding of both the science and clients’ specific objectives, we ensure innovations reach the right audiences with impact.
Our writing translates innovations in metabolic diseases
Numerous important developments in metabolic disease treatments have been seen in recent times, especially in obesity and type 2 diabetes
At Elion, we’ve been proud to support a variety of clients, helping to translate complex science into engaging communications. With our deep understanding of both the science and clients’ specific objectives, we ensure innovations reach the right audiences with impact.
Metabolic disease areas we have supported
Glucagon-like peptide (GLP)-1 receptor agonists in diabetes and obesity
With their significant benefits in blood sugar control and weight loss, GLP-1 receptor agonists, also known as GLP-1 inhibitors, have been reshaping the treatment landscape for type 2 diabetes and obesity. Recent developments include next-generation medicines designed to enhance efficacy and tolerability and once-monthly injectables and oral formulations to make treatments more accessible and appealing to a broader patient population.
Other diabetes medicines
Sodium glucose co-transporter 2 (SGLT2) inhibitors, also known as gliflozins, have also had a notable impact on the diabetes landscape. These medications work by promoting glucose excretion through the urine. They’ve gained popularity because of their cardiovascular and renal protective effects and ability to lower blood sugar. Other medicines that continue to develop in this space include dipeptidyl peptidase 4 (DPP-4) inhibitors and nonsteroidal mineralocorticoid receptor blockers.
Continuous glucose monitoring (CGM) devices
CGM technology has seen some exciting leaps forward in recent years, making diabetes simpler to manage. Some of the standout developments include smaller, longer-lasting sensors; enhanced mobile integration; and closed-loop systems where CGMs are integrated with automated insulin delivery systems.
Diabetic macular oedema
Diabetic macular oedema is a common complication of diabetic retinopathy and has traditionally been considered largely related to glycated haemoglobin levels. Recent evidence suggests other causes, including the albuminuria resulting from diabetic nephropathy. This knowledge may have implications when it comes to assessing patients for risk of diabetic macular oedema and for potential future treatment strategies.
Our work in metabolic diseases
Elion’s team includes skilled medical writers with experience in developing:
- Manuscripts for clinical studies
- Review articles
- Website content for obesity and diabetes awareness campaigns
- Content for product launches of GLP-1 receptor agonists
- Core claims documents
- Patient booklets
- Dosing and prescribing guidelines
- Direct-to-consumer campaigns
- Training slide decks
- Leave behinds
- Case studies
Metabolic disease types:
- Type 1 and 2 diabetes
- Familial hypercholesterolemia
- Gaucher disease
- Fabry disease
- Pompe disease
- Maple syrup urine disease
- Phenylketonuria (PKU)
- Mitochondrial disorders
- Glycogen storage disease.
Our approach sets us apart
At Elion, we have the capabilities to provide support throughout a product’s lifecycle.
This includes from early research to market launch and on to the later stages of a product’s lifecycle when losing exclusivity and facing competition from generics or biosimilars.
01
Define
Aligning on goals: we begin with a kick-off call and written brief to clarify objectives, timelines, audience, and deliverables. This ensures a shared understanding and smooth project setup.
02
Create
Developing content: we draft clear and engaging content in collaboration with your team. Messaging is grounded in evidence and tailored for your audience.
03
Refine
Reviewing and improving: we edit, fact check and integrate feedback to ensure accuracy, consistency and alignment with industry standards.
04
Enhance
Optimising outputs: we refine visuals, formatting and structure to maximise impact and engagement across all intended channels.
05
Deliver
Finalising and measuring impact: we prepare final deliverables, ready for submission, presentation or distribution. We can also help define success metrics and gather performance insights to inform future projects.
Expertise in metabolic diseases writing
We’d love to discuss how we can support your next project in metabolic diseases.
We understand the demands of producing clear content in diabetes, obesity and related conditions. Our writers bring expertise in GLP‑1s, SGLT2 inhibitors, CGM technologies and more to your communications.
Metabolic disease FAQs
Metabolic diseases such as obesity and type 2 diabetes carry significant stigma, often portrayed in oversimplified or blaming terms. At Elion, we craft empathetic, evidence-based language that respects the individual and avoids shame. By using person-first phrasing (‘people living with obesity’) and avoiding a moralising tone, we help promote positive engagement, adherence and trust.
We are skilled at crafting feature-based selling messages without making unsubstantiable or misleading claims, useful for content about a product or service with limited or emerging evidence. These may include lifestyle interventions or alternative or complementary therapies. We can also harness brand identity, transparent storytelling, user insights and case studies to make a product or service shine, without overpromising.
We keep the client’s objectives in mind as we consider the different priorities, knowledge levels and literacy of the target audience, be they patients, the general public, healthcare professionals, payers, researchers or advocacy groups. Our team of writers come from various backgrounds, helping to support our understanding of the needs of these diverse audiences.
Project timelines can vary according to scope and complexity. Thanks to our global team and the time zone advantage of the team based in New Zealand, we can work around the clock to deliver quickly — even quicker than in-house teams! This holds especially true for urgent projects.
AI tools can assist with drafting or refining content, but they are known to have issues with some aspects of medical writing or copywriting. For instance, humans have a proper understanding of complex topics, know how to use the right kinds of references to substantiate data, can ensure content meets relevant regulations relating to promotion of medicines or devices and can ensure writing is empathetic in areas that are sensitive or may have a social stigma attached. If you choose to use AI, Elion can support you by carefully checking and editing AI-generated content for scientific accuracy and coherence, producing reference packs to be used for approval processes, reviewing content against relevant regulations and reviewing for empathetic tone and cultural appropriateness.
Absolutely! Our medical writers are experienced in assisting with publication planning and audience-targeting strategies, helping you shape your communications for maximum impact.
Yes, our team is well-versed in collaborating with international, cross-functional teams. We’re familiar with both global and local review and approval processes.
At Elion, we have two decades of experience in project planning. Every project is approached with clear strategic planning and transparency. That includes upfront scoping, well-defined goals and prioritising the tactics that deliver the most impact for your budget. We also know agility matters. We work collaboratively with our clients to re-evaluate and re-prioritise if unexpected challenges arise, always with transparency and focusing on delivering value.
